Showing 2751-2760 of 4087 results for "".
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- Analysis: IL-17, JAK Inhibitors May Carry Elevated Risk for TBhttps://practicaldermatology.com/news/analysis-il-17-jak-inhibitors-may-carry-elevated-risk-for-tb/2483387/A large population-based analysis using data from TriNetX suggests a elevated risk of active tuberculosis (TB) in patients treated with systemic immunosuppressive therapies (including IL-17, IL-23, IL-12/23, Janus kinase (JAK) inhibitors), cyclosporine, and tumor ne
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- From ASLMS 2025: Dr. Joel Cohen Highlights New Fractional Laser Techniques, Including Laser-enabled Tissue Coringhttps://practicaldermatology.com/news/from-aslms-dr-joel-cohen-highlights-new-fractional-laser-techniques-for-scars-at-aslms/2474327/During a fractional laser section of the recent program of the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, board-certified dermatologist, Mohs surgeon, and laser expert Joel L. Cohen, MD, FAAD, FACMS, presented clinical insights into fractional laser us
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- JAK Inhibitors' Applications Continue to Expandhttps://practicaldermatology.com/news/JAK-Inhibitors-Applications-Continue-Expand/2471523/While JAK inhibitors have become widely popular for several common skin diseases, their potential for other indications remains vast, and Ruth Ann Vleugels, MD, MPA, MPH, FAAD, highlighted some of these in “JAK Inhibitors for Lupus, Dermatomyositis, and SAVI” at the 2025 American Academy of Derma
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s